Resistance Oncology ApS: Financial statements 2018
CVR: 36945125
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -14,500 and a net result of DKK -12,643 compared with DKK 1,147,497 the year before. Equity in the 2018 report amounted to DKK -24,797.
- Gross Profit
- DKK -14,500
- Profit/Loss
- DKK -12,643
- Equity
- DKK -24,797
- Total Assets
- DKK 43,403
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -15 t. | -13 t. | -25 t. | - |
| 2017 | - | 51 t. | 1.1 mio. | -12 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Resistance Oncology ApS has published its annual report for 2017. Gross profit came to DKK 51,356, and the net result was DKK 1,147,497.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.